Q1 Earnings Estimate for VYGR Issued By Leerink Partnrs

Voyager Therapeutics, Inc. (NASDAQ:VYGRFree Report) – Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Voyager Therapeutics in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo anticipates that the company will earn ($0.17) per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS and Q4 2025 earnings at ($0.17) EPS.

Several other equities analysts have also weighed in on VYGR. Wedbush initiated coverage on shares of Voyager Therapeutics in a research report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price objective on the stock. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald began coverage on shares of Voyager Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating and a $5.73 price target on the stock. Finally, StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Voyager Therapeutics has an average rating of “Buy” and an average price target of $15.97.

View Our Latest Analysis on Voyager Therapeutics

Voyager Therapeutics Price Performance

Shares of VYGR opened at $5.62 on Friday. The firm has a market capitalization of $307.02 million, a PE ratio of 7.92 and a beta of 0.93. The company’s 50-day moving average is $5.80 and its 200-day moving average is $6.64. Voyager Therapeutics has a fifty-two week low of $4.99 and a fifty-two week high of $10.66.

Voyager Therapeutics (NASDAQ:VYGRGet Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. The company had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the prior year, the firm earned ($0.59) earnings per share.

Institutional Investors Weigh In On Voyager Therapeutics

A number of large investors have recently bought and sold shares of VYGR. China Universal Asset Management Co. Ltd. boosted its stake in shares of Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after purchasing an additional 4,098 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at approximately $74,000. Hsbc Holdings PLC acquired a new stake in shares of Voyager Therapeutics in the 2nd quarter valued at approximately $128,000. SG Americas Securities LLC boosted its stake in shares of Voyager Therapeutics by 86.7% in the 4th quarter. SG Americas Securities LLC now owns 23,044 shares of the company’s stock valued at $131,000 after purchasing an additional 10,704 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at approximately $216,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 10,778 shares of company stock worth $58,548 over the last ninety days. Corporate insiders own 4.53% of the company’s stock.

About Voyager Therapeutics

(Get Free Report)

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

Further Reading

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.